Format

Send to

Choose Destination
Ann Dermatol Venereol. 2014 May;141(5):354-63. doi: 10.1016/j.annder.2014.03.009. Epub 2014 Apr 13.

[Oral toxicity of targeted anticancer therapies].

[Article in French]

Author information

1
Dermatologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, institut universitaire du cancer, Toulouse Oncopole, 1, avenue Irene-Joliot-Curie, 31100 Toulouse cedex, France. Electronic address: sibaud.vincent@iuct-oncopole.fr.
2
Dermatologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, unité de dermatologie pédiatrique, hôpital Pellegrin enfants, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
3
Odontologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, institut universitaire du cancer, Toulouse Oncopole, 1, avenue Irene-Joliot-Curie, 31100 Toulouse cedex, France.
4
Unité de médecine bucco-dentaire, consultation pluridisciplinaire de pathologie de la muqueuse buccale, UFR odontologie Bordeaux, 16-20, cours de la Marne, 33076 Bordeaux cedex, France; Pôle odontologie et santé buccale, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.

Abstract

While toxicity of targeted anticancer therapies on the oral mucosa seems relatively frequent in clinical practice, it has not been properly characterized to date, apart from aphthous-like lesions due to mTOR inhibitors. Herein, we report the main oral lesions associated with these new therapies, with a description of the most frequent but also the most characteristic clinical manifestations of these drugs, such as anti-EGFR-induced mucositis, BRAF-inhibitor-associated hyperkeratosis, benign migratory glossitis and osteonecrosis of the jaw observed with angiogenesis inhibitors, as well as lesions more specifically linked with imatinib.

KEYWORDS:

Aphthous-like lesions; Benign migratory glossitis; Glossite migratrice bénigne; Hyperkeratosis; Hyperkératose; Lésions buccales; Mucite; Mucositis; Oral lesions; Osteonecrosis of the jaw; Ostéonécrose de la mâchoire; Targeted therapies; Thérapies ciblées; Ulcérations aphtoïdes

PMID:
24835648
DOI:
10.1016/j.annder.2014.03.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center